Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2008 Q1- Text added to 2008 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Good
|
New words:
Abciximab, abetting, Accentia, accrual, Actimmune, aiding, allegedly, anemia, Antisoma, anytime, arm, attributable, Axitinib, began, BioVaxID, Bowel, breach, burdensome, cardiotoxic, Chancery, Citigroup, composed, conclusion, confounding, converting, Dear, declaratory, Delaware, distraction, docetaxel, driver, duty, enhanced, enrichment, entity, Estrogen, expenditure, EXPLORER, family, fatal, feature, fiduciary, gave, Goldman, Harkonen, HCP, hemolytic, immunosuppression, improper, inapplicable, Indenture, infliximab, InterMune, Kingdom, leukoencephalopathy, lifted, LLC, MAHA, Master, Mateo, member, microangiopathic, modification, multifocal, network, Northern, NSABP, opt, optimize, payor, pipeline, Piramed, PML, point, preceded, presidential, properly, prosecute, prosecutor, purported, racketeering, recipient, REFLEX, renew, ReoPro, replying, RIBBON, SABRE, salable, Scott, shareholder, similarly, Slough, smaller, sponsored, SSF, standalone, submission, subset, Surgical, Takeda, trend, trustee, unjust, unsalable, unsolicited, Ustekinumab, view, VSP, York
Valuein 2008 Q1 filing- Value in 2008 Q2 filing
Original filings
Filing view